



1 Analysis of fatality among COVID-19 cases in Mexican pregnant women: a cross-sectional study

2 Short title: Fatality and COVID-19 in pregnancy

3 Nicolás Padilla-Raygoza^{*1#a}, María de Jesús Gallardo-Luna¹, Gilberto Flores-Vargas¹, Efrain Navarro-

4 Olivos^{2#b}, Francisco J. Magos-Vázquez^{3#c}, Elia Lara-Lona^{3#c}, Daniel A. Díaz-Martínez^{3#c}

5 ^{1#a} Department of Research and Technological Development, Directorate of Teaching and

6 Research, Institute of Public Health from Guanajuato State, Guanajuato, Gto., México

7 ^{2#b} Directorate of Teaching and Research, Institute of Public Health from Guanajuato State,

8 Guanajuato, Gto., Mexico

9 ^{3#c} Directorate of Health Services. Institute of Public Health from Guanajuato State, Guanajuato,

10 Gto., Mexico

11

12 Current Address:

13 ^{#a} Department of Research and Technological Development, Víctor Cervera Pacheco #14 Primer

14 Piso, Plaza Santa Fé, Guanajuato, Gto., Mexico

15 Current Address:

16 ^{#b} Directorate of Teaching and Research, Víctor Cervera Pacheco #14 Primer Piso, Plaza Santa Fé,

17 Guanajuato, Gto., Mexico CP36250

18 Current Address:

19 ^{#c} Directorate of Health Services, Tamazuca #4, Guanajuato, Gto., Mexico CP36000

20

21 * Corresponding Author



22 E-mail: npadillar@guanajuato.gob.mx (NP-R)

23 **Abstract**

24 This study aims to analyze the fatality of cases confirmed by COVID-19 among
25 pregnant women in Mexico. It is a cross-sectional and analytical study. We used the
26 registries from pregnant women available in the open database of the National
27 Epidemiological Surveillance System from the General Directorate of Epidemiology. We
28 showed descriptive statistics for all the variables. A suspected case of COVID-19 is any
29 person who presented the following signs and symptoms: fever, headache, cough, and
30 others. A confirmed case is any suspected case with a positive RT-PCR test result. We
31 computed OR and 95% confidence intervals to estimate the effect of independent variables
32 on dying from COVID-19. Also, it was calculated the Case Fatality Ratio (CFR) among
33 pregnant women. The alpha value was fixed at 0.05 as a threshold to show statistical
34 significance. The CFR was 1.09%. For confirmed cases, the average age among those who
35 died was higher than among those who did not die ($P < 0.05$). The average time between the
36 onset of symptoms and registration in the system was higher for those who died ($P < 0.05$).
37 Among the deceased, 76.97% had pneumonia. For the 40-49 years age group, the effect on
38 death was statistically significant (OR 4.97, CI95% 1.77 – 17.85). Outpatient care had a
39 protective effect on dying (OR 0.04, CI95% 0.02 – 0.09). Pneumonia was highly associated
40 with death (OR 8.68, CI95% 5.72 – 13.6). Co-morbidities did not affect dying while
41 considering them in a multivariable logistic regression model. Among pregnant women,
42 smoking has little effect on death by COVID-19. The CFR was low compared with the rest
43 of the Mexican population. The co-morbidities had a low prevalence among pregnant



44 women. Since the reproductive age span is young age, pregnant women have two protective
45 factors for COVID-19 detected so far: being young and woman.

46 **Keywords:** SARS-CoV-2, COVID-19, Reproductive age, Fatality; Surveillance system,
47 Pregnancy

48 **Introduction**

49 In November-December 2019, several cases of pneumonia of unknown origin were
50 detected in Wuhan, China [1]. After genomic analyses, the pathogen responsible was
51 determined and called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
52 Meanwhile, the disease was named Coronavirus Disease 2019 (COVID-19) [2]. Since then,
53 this disease has spread to the entire world. By November 1, 2021, 246,594,191 cases and
54 4,998,784 deaths have been reported in 224 countries [3].

55 Pregnant women are likely to represent a high-risk population in the COVID-19
56 pandemic. Although pregnant women infected with SARS-CoV-2 are predominantly
57 asymptomatic or present mild COVID-19 -very similar to non-pregnant women [4]- they
58 may be at higher risk of severe COVID-19 than the general population, according to
59 Wastnedge et al. [5].

60 In a report from seven pregnant women infected by SARS-CoV-2 in Wuhan, China,
61 all were in the last pregnancy trimester and had contact with the epidemic area, but not with
62 food from the seafood market in the same city. The median age was 32 years -spreading
63 between 29 and 34 years- and none was required to be treated in the ICU [6].

64 Pregnant women are considered a group at risk during the pandemic by SARS-CoV-
65 2 due to biological processes related to pregnancy. It is hypothesized that a shift in the CD4



66 + cell population towards the Th2 phenotype, promoting the humor response, mediates the
67 altered inflammatory response to viruses during pregnancy. The Th2 and Th1 response has
68 been implicated in the pathogenesis of severe COVID-19 [7]. Also, during pregnancy, a
69 decrease in natural killer (NK) cells occurs [8], and the NKs participate in virus
70 neutralization [9]. The effect of the NK decreasing in the clinical picture of COVID-19 is
71 unknown. There are other immune effects as progesterone levels [10] and alterations in
72 Toll-like receptors (TLRs) [11]. It remains to be elucidated whether they have protective or
73 harmful effects on pregnant women with COVID-19 [5]. Besides, the reduction in total
74 lung capacity and the inability to expel secretions can make pregnant women more
75 susceptible to severe respiratory infections [12].

76 Pregnancy is also a hypercoagulable state, with increased thrombin production and
77 intravascular inflammation [13]. On the other hand, COVID-19 has been associated with
78 thromboembolic complications in 31% of the patients reported in Knight M et al. [14].

79 According to Lopez-Rodriguez et al. [15], in 29,416 pregnant Mexican women,
80 39% had a COVID-19-positive diagnosis. They found that the risk of death was three times
81 higher among those positive for COVID-19 than those who tested negative.

82 This paper aims to analyze the cases of COVID-19 in pregnant women registered in
83 the open and public database of the National Epidemiological Surveillance System (NESS)
84 from the General Directorate of Epidemiology (GDE) of the Ministry of Health (MH) [16]
85 and their association with comorbidities.

86 **Material and methods**



87 The study was approved by the Research Ethics Committee from the Salamanca
88 General Hospital, Mexico.

89 **2.1 Study design**

90 It is a cross-sectional and analytical study.

91 As a requisite to be tested, pregnant women must meet the operational definition of
92 suspected cases of respiratory viral infection (17). A suspected case of viral disease is
93 considered as anyone who presents fever, headache, cough, or dyspnea (signs of severity),
94 in addition to one of the following: myalgias, arthralgias, odynophagia, chills, chest pain,
95 rhinorrhea, anosmia, dysgeusia, or conjunctivitis. If a subject meets the operational
96 definition, the subject undergoes a nasopharyngeal Real-Time Polymerase Chain Reaction
97 (RT-PCR) test (17).

98 The variables included in the database are the following: state of residence, age,
99 date of onset of symptoms, date of registration, date of death (if it occurred), hospital or
100 outpatient management, pneumonia diagnosis, underlying presence of diabetes, Chronic
101 Obstructive Pulmonary Disease (COPD), asthma, immunosuppression, hypertension,
102 cardiovascular disease, chronic kidney disease, obesity, or smoking. The diagnosis tool for
103 COVID-19 was the real-time polymerase chain reaction test (RT-PCR) (16, 17).

104 The database does not record gestational age at the time of positive diagnosis for
105 SARS-CoV-2.

106 After the approval of the research protocol by the ethics committee for research, we
107 downloaded the open database of the NESS/GDE, and we preprocessed it to verify the data



108 consistency. The dataset was analyzed in STATA 13.0 ® (Stata Corp., College Station, TX,
109 USA). NESS/GDE database does not include personal data.

110 **2.2 Statistical analysis**

111 Descriptive statistics are presented for all the variables. To compare quantitative
112 variables between confirmed COVID-19 cases, deceased or not, the Student t-test was
113 performed. To compare categorical variables, the Chi-squared was used. Odds Ratio (OR)
114 and 95% confidence intervals (95%CI) were calculated to estimate the effect of
115 independent variables on dying from COVID-19. Also, it was calculated the Case Fatality
116 Ratio (CFR) among pregnant women. In all cases, the corresponding P-values are present.
117 Also, to demonstrate the statistical significance of the results, the alpha value was set at
118 0.05. Statistical analysis was performed in STATA 13.0 ® (Stata Corp., College Station,
119 TX, USA).

120

121 **Results**

122 **Description of the pregnant women population**

123 In the NESS/GDE database, 42,334 pregnant women were reported; from them, 13,891
124 (32.81%) tested positive for SARS-CoV-2 and 28,443 (67.19%) tested negative (16).

125 **Characterization of death cases**

126 Both SARS-CoV-2 positive and negative pregnant women had an age range of 12 to
127 49 years and a mean of 28.41 ± 6.13 years for the former and 27.09 ± 6.36 years for the



128 latter -the difference was statistically significant ($P = .00001$)-. According to the database,
 129 the difference between the onset of symptoms and registry into the system, on average, is
 130 higher among COVID-19 cases than among negative ones ($P < .05$) (Table 1).

131 The CFR was 152/13,739 (1.1%). For confirmed cases, the average age among the
 132 deceased cases was greater than among those who did not die ($P < 0.05$). The average time
 133 between the onset of symptoms and registration into the system was greater among those
 134 who died. ($P < 0.05$) (Table 1).

135 **Table 1 Distribution of quantitative variables among deaths and non-deaths by**
 136 **COVID-19 in Mexican pregnant**

Variable	Confirmed COVID-19 cases		t-test, df, <i>P</i> -value
	Deaths (n=152)	Non-deaths (n=13,739)	
Age (years)			
Minimum to maximum	16 to 49	12 to 49	6.42, 13889, <0.001
Mean ± S	31.59 ± 6.89	28.38 ± 6.12	
Time between beginning of symptoms and date of registry (days)			
Minimum to maximum	0 to 16	0 to 39	4.96, 13899, <0.001
Mean ± S	4.90 ± 3.55	3.68 ± 3.06	

137 **Abbreviations:** df degree of freedom

138

139 Between pregnant women positive for COVID-19, the CFR by age group were: 12-
 140 19 years, 0.44%, 20-29 years, 0.78%, 30-39 years, 1.36%, and 40-49 years, 3.74%.

141 The predominant age group among the deceased cases was 30-39 years (47.37%).
 142 Meanwhile, in the non-deceased, those aged 20 to 29 years (51.63%) ($P < 0.05$)
 143 predominated.



144 **Associated risk factors for lethality**

145 Among the deceased cases, hospitalized patients predominated (93.42%). Compared
 146 with the non-deceased, where most subjects received outpatient management (82.27%) (P
 147 <0.05). Among the deceased, 76.97% had pneumonia. Among the non-deceased, only
 148 17.73% had it (P <0.05). A statistically significant relationship with death (P <0.05) was
 149 found for diabetes, COPD, asthma, immunosuppression, hypertension, chronic kidney
 150 disease, obesity, and smoking (Table 2).

151 **Table 2 Relationship between variables and deaths by COVID-19 in Mexican**
 152 **pregnant women.**

	Confirmed COVID-19 cases				X ² , df, P-value
	Deaths		Non-deaths		
	n	%	n	%	
Age group (years)					
12 to 19	4	2.63	897	6.53	47.86, 3, <0.001
20 to 29	56	36.84	7094	51.6	
30 to 39	72	47.37	5233	38.1	
40 to 49	20	13.16	515	3.75	
Care type					
Hospitalized	142	93.42	2436	17.7	569.84, 1, <0.001
Ambulatory	10	6.58	11303	82.3	
Pneumonia					
Yes	117	76.97	952	6.93	1000.03, 1, <0.001
No	35	23.03	12787	93.1	
Diabetes					
Yes	20	13.16	414	3.01	74.04, 1, <0.001
No	130	85.53	13313	96.9	
Chronic Obstructive Pulmonary Disease					
Yes	0	0	21	0.15	*-4.17, <0.001
No	149	98.03	13706	99.8	
Asthma					
Yes	5	3.29	279	2.03	28.15, 1, <0.001
No	145	95.39	13450	97.9	
Immunosuppression					
Yes	2	1.32	91	0.66	17.70, 1, <0.001
No	148	97.37	13632	99.2	



Hypertension					
Yes	15	9.87	362	2.63	35.74, 1, <0.001
No	136	89.47	13366	97.3	
Cardiovascular Disease					
Yes	0	0	59	0.43	*-1.38, 0.17
No	150	98.68	13669	99.5	
Chronic Kidney Disease					
Yes	3	1.97	39	0.28	35.09, 1, <0.001
No	147	96.71	13687	99.6	
Obesity					
Yes	26	17.11	1026	7.47	29.76, 1, <0.001
No	125	82.24	12706	92.5	
Smoking					
Yes	2	1.32	262	1.91	27.27, 1, <0.001
No	148	97.37	13467	98	

153 Notes: * Z for two proportions

154

155 Using the logistic regression model that included all the variables with a statistically
 156 significant relationship with death, an effect on dying was detected for the age group from
 157 40 to 49 years (OR 4.97 95%CI 1.77-17.85). The difference in days between the onset of
 158 symptoms and system registration is in the border area. The type of outpatient care has a
 159 protective effect on dying (OR 0.04 95%CI 0.02-0.09). Meanwhile, Pneumonia shows a
 160 high association (OR 8.68 95%CI 5.72-13.6). Diabetes, asthma, immunosuppression,
 161 hypertension, chronic kidney disease, and obesity did not affect death. As seen in the
 162 variance inflation factor (VIF), these variables may be highly correlated. Hence, they have
 163 little influence on the model. Smoking has little effect on death due to COVID-19 among
 164 pregnant women (Table 3). We fitted a model by omitting diabetes, immunosuppression,
 165 hypertension, and chronic kidney disease -those with higher VIF, different age groups, and
 166 non-statistically significant effects-. The Bayesian Information Criteria decreased from
 167 1217.52 in the original model to 1190.26. The likelihood ratio test showed a statistically



168 significant difference between the models. Nevertheless, the qualitative results were the
 169 same.

170 **Table 3 Logistic regression model including all independent variables with death in**
 171 **Mexican pregnant women**

Deaths	OR	(95% CI) adjusted	VIF
Age group	Reference group	-----	
12-19			
20 – 29	1.67	(0.66 - 5.68)	8.97
30 – 39	2.34	(0.93 - 7.92)	9.39
40 – 49	4.97	(1.77 - 17.85)	4.55
Difference in days	1.04	(0.99 - 1.09)	1.02
Care type	0.04	(0.02 - 0.09)	1.27
Pneumonia	8.68	(5.72 - 13.6)	1.22
Diabetes	0.98	(0.89 - 1.04)	9.56
Chronic Obstructive Pulmonary Disease	1.07	(1.04 - 1.11)	2.66
Asthma	1.05	(1 - 1.1)	4.48
Immunosuppression	0.95	(0.84 - 1.03)	49.11
Hypertension	0.97	(0.87 - 1.02)	16.02
Chronic kidney disease	0.99	(0.87 - 1.06)	32.98
Obesity	0.96	(0.87 - 1.01)	1.68
Smoking	1.05	(1.01 - 1.09)	1.91

172 **Notes:** VIF Variance inflation factor

173

174 Discussion

175 The CFR reported by Padilla et al. [18] for the Mexican population on May 15,
 176 2020 (10.59%) was higher than the one for the sample in this study (1.1%). Padilla et al.
 177 [18] also mentions that 68.14% of the deaths were in males and 49.57% in those over 60
 178 years.



179 Table 2 reports a relationship between the study variables and death from COVID-
180 19, except for cardiovascular disease. When quantifying the effect of these variables, only
181 the age group, the difference in days between the onset of symptoms and the registration in
182 the system, the type of care, pneumonia, COPD, asthma, and smoking affected death (Table
183 3).

184 Of nine pregnant women with COVID-19 and pneumonia, none developed severe
185 pneumonia or died, as reported by Cheng et al. [19]. In the sample of Mexican pregnant
186 women, 18.56% were hospitalized, 7.70% developed pneumonia, and 1.09% died (Table
187 2). In a series of 116 cases of pregnant women with COVID-19, 8% developed pneumonia
188 [20], like the results in this study. Yu et al. [21] reported 124 maternal deaths in Brazil
189 between February and June 2020. At the same time, Mexico reported seven maternal deaths
190 [22]. The increase in maternal mortality from COVID-19 in Brazil may be due to a
191 decreased availability of health professionals or a lack of intensive care units.

192 There is no evidence that pregnant women are more susceptible to SARS-CoV-2
193 [23].

194 In the analysis of the relationship between different variables with dying from
195 COVID-19 was found that age group, hospitalization, pneumonia, diabetes, COPD, asthma,
196 immunosuppression, hypertension, chronic kidney disease, obesity, and smoking are related
197 to death from COVID-19 ($P < 0.05$) (Table 2). Nevertheless, these relationships are lost
198 when analyzing the logistic regression model that included all the variables associated with
199 death from COVID-19.

200 The age group of 40-49 years shows an effect on dying from COVID-19 (OR =
201 4.97, 95% CI 1.61 -15.36). The age group from 40 to 49 years had the higher CFR, 3.74%.



202 The difference in days between the onset of symptoms and the date of registry in the
203 NESS/DGE system is at the limit of statistical significance (OR = 1.04, 95% CI 1.00-1.09).
204 Pneumonia is the one variable with the highest effect on dying (OR = 8.68, 95% CI 5.64 -
205 13.37). COPD, asthma, and smoking show ORs close to 1 (Table 3), which indicates a
206 slight effect.

207 Pneumonia showed the highest OR on death from COVID-19 (Table 3), consistent
208 with previous reports concerning children and adults, where the principal cause of death
209 was pneumonia.

210 The underlying pathologies that aggravate COVID-19 in the general population
211 seem to have minor effects on the severity of COVID-19 in pregnant women.

212 Pregnant women have been considered a risk group for COVID-19. In the database
213 analyzed, the co-morbidities did not play a statistically significant role in death while
214 integrating them in a multivariable logistic regression model, except for COPD and asthma.
215 Also, health care workers must monitor the development of pneumonia because it is
216 significantly related to death. A substantial limitation of this study is the absence of data
217 about gestational age. This variable could play a confounding role in mortality. It is worth
218 noting that some deaths occurred among pregnant women with ambulatory care. It should
219 be addressed in further research. Due to the limitations of the database, it was not possible
220 in this study.

221 **Conclusion**

222 As in the general population, older age and pneumonia relate to death. The co-
223 morbidities had a low prevalence among pregnant women. Since the reproductive age



224 usually ends at 50, pregnant women have two protective factors for COVID-19 detected in
225 the literature: being young and woman. They have been two inherent confounding factors
226 in this study.

227 **References**

- 228 1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan,
229 China: the mystery and miracle. *J Med Viral* (2020) 92(94):401-402. Doi:
230 <http://doi.org/10.1002/jmv.25678>
- 231 2. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin,
232 transmission, and characteristics of human coronaviruses *J Adv Res* (2020) 24: 91–98.
233 Doi: <https://doi.org/10.1016/j.jare.2020.03.005>
- 234 3. Secretariat of Health. Novel Coronavirus in the World: COVID-19. Technical
235 Communicate Daily (2021).
236 ([https://www.gob.mx/cms/uploads/attachment/file/678900/Comunicado_Tecnico_Diario](https://www.gob.mx/cms/uploads/attachment/file/678900/Comunicado_Tecnico_Diario_COVID-19_2021.11.01.pdf)
237 [_COVID-19_2021.11.01.pdf](https://www.gob.mx/cms/uploads/attachment/file/678900/Comunicado_Tecnico_Diario_COVID-19_2021.11.01.pdf)) [Accessed November 3, 2021]
- 238 4. Salem D, Katranji F, Bakdash T. COVID-19 infection in pregnant women; Review of
239 maternal and fetal outcomes. *International Journal of Gynecology & Obstetrics* (2020)
240 152(3):291-298. Doi: <https://doi.org/10.1002/ijgo.13533>
- 241 5. Wastnedge EAN, Reynolds RM, van Boeckel SR, Stock SJ, Denison FC, Maybin JA et
242 al. Pregnancy and COVID-19. *Physiol Rev* (2021) 101(1):303-318. doi:
243 <https://doi.org/10.1152/physrev.00024.2020>



- 244 6. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and
245 neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a
246 restrospective, single centre, descriptive study. *Lancet Infec Dis* (2020) 20(5): 559-564.
247 Doi: [https://doi.org/10.1016/S1473-3099\(20\)30176-6](https://doi.org/10.1016/S1473-3099(20)30176-6)
- 248 7. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Pathogenic T-cells and
249 inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. *Nat*
250 *Sci Rev* (2020) 7:998-1002. doi: <https://doi.org/10.1093/nsr/nwaa041>.
- 251 8. Veenstra van Nieuwenhoven AL, Heineman MJ, Faas MM. The immunology of
252 successful pregnancy. *Hum Reprod Update* (2003) 9:347-357. Doi:
253 <https://doi.org/10.1093/humupd/dmg026>
- 254 9. Brandstadter JD, Yang Y. Natural killer cell responses to viral infection . *J Innate Immun*
255 (2011) 3:274-279. Doi: <https://doi.org/10.1159/000324176>
- 256 10. Siiteri PK, Febres F, Clemens LE, Chang RJ, Gondos B, Stites D. Progesterone and
257 maintenance of pregnancy: is progesterone nature's immunosuppressant? *Ann N Y*
258 *Acad Sci* (1977) 286 (1 Biochemical A): 384-397. Doi:
259 <https://doi.org/10.1111/j.1749-6632.1977.tb29431.x>.
- 260 11. Young BC, Stanic AK, Panda B, Rueda BR, Panda A. Longitudinal expression of Toll-
261 like receptor son dendritic cells in uncomplicated pregnancy and postpartum. *Am J*
262 *Obstet Gynecol* (2014) 210:445.e1-445.e6. Doi:
263 <https://doi.org/10.1016/j.ajog.2013.11.037>
- 264 12. Goodnight WH, Soper DE. Pneumonia in pregnancy. *Crit Care Med* (2005)
265 33(Suppl):S390-S397. Doi: <https://doi.org/10.1097/01.CCM.0000182483.24836.66>



- 266 13. Di Renzo GC, Giardina I. Coronavirus disease 2019 in pregnancy consider
267 thromboembolic disorders and thromboprophylaxis. *Am J Obstet Gynecol* (2020)
268 223(1):135. Doi: <https://doi.org/10.1016/j.ajog.2020.04.017> 2020.
- 269 14. Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics
270 and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2
271 infection in UK: national population-based cohort study. *BMJ* (2020) 369:m2107. Doi:
272 <https://doi.org/10.1136/bmj.m2107>
- 273 15. Lopez-Rodriguez G, Galvan M, Galvan-Valencia O. Comorbidities associated with
274 maternal mortality from COVID-19 in Mexico. *Gac. Med. Mex* 2021; 157 (6): 618-
275 622. Doi: <https://doi.org/10.24875/gmm.21000221>
- 276 16. General Directorate of Epidemiology. Sub-secretary of Prevention and Promotion of
277 Health. Historical open databases (March 31, 2021).
278 [https://www.gob.mx/cms/uploads/attachment/file/673724/Datos_abiertos_hist_ricos_2](https://www.gob.mx/cms/uploads/attachment/file/673724/Datos_abiertos_hist_ricos_2021.pdf)
279 [021.pdf](https://www.gob.mx/cms/uploads/attachment/file/673724/Datos_abiertos_hist_ricos_2021.pdf) [Accessed November 1, 2021]
- 280 17. General Directorate of Epidemiology. Secretary of Health. Updating of the operational
281 definition of a suspected case of viral respiratory disease (August 24, 2020).
282 [https://www.gob.mx/cms/uploads/attachment/file/573732/Comunicado_Oficial_DOC_](https://www.gob.mx/cms/uploads/attachment/file/573732/Comunicado_Oficial_DOC_sospechoso_ERV_240820.pdf)
283 [sospechoso_ERV_240820.pdf](https://www.gob.mx/cms/uploads/attachment/file/573732/Comunicado_Oficial_DOC_sospechoso_ERV_240820.pdf). [Accessed November 1, 2021]
- 284 18. Padilla-Raygoza N, Sandoval-Salazar C, Díaz-Becerril LA, Beltrán-Campos V, Díaz-
285 Martínez DA, Navarro-Olivos E, et al. Update of the Evolution of SARS-CoV-2
286 Infection, COVID-19, and Mortality in Mexico Until May 15, 2020: An Ecological



- 287 Study. *International Journal of TROPICAL DISEASE & Health* (2020) 41(5): 36-45.
288 Doi: <https://doi.org/10.9734/IJTDH/2020/v41i530277>
- 289 19. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and
290 intrauterine vertical transmission potential of COVID-19 infection in nine pregnant
291 women: a retrospective review of medical records. *Lancet* (2020) 395:809-815. Doi:
292 [https://doi.org/10.1016/S0140-6736\(20\)30360-3](https://doi.org/10.1016/S0140-6736(20)30360-3).
- 293 20. Yan J, Guo J, Fan C, Juan J, Yu X, Li J, et al. Coronavirus disease 2019 (COVID-19 in
294 pregnant women : A report based on 116 cases . *Am J Obstet Gynecol* (2020)
295 223(1):111.e1-111.e14. Doi: <https://doi.org/10.1016/j.ajog.2020.04.014>
- 296 21. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and
297 neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a
298 retrospective, single-centre, descriptive study. *Lancet Infect Dis* (2020) 20:559-564.
299 Doi: [https://doi.org/10.1016/S1473-3099\(20\)30176-6](https://doi.org/10.1016/S1473-3099(20)30176-6).
- 300 22. Takemoto ML, Menezes MO, Anfreucci CB, Nakamura-Pereira M, Armorim MMR,
301 Katz L, et al. The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting.
302 *Int J Gynaecol Obstet* (2020) 1(1):154-156. Doi: <https://doi.org/10.1002/ijgo.13300>
- 303 22. Rajewska A, Mikolajek-Bedner W, Lebdowicz-Knul J, Sokołowska M, Kwiatkowski S,
304 Torbé A. COVID-19 and pregnancy-where are we now? A review. *J Perinat Med*
305 (2020) 48(5):428-434. Doi: <http://doi.org/10.1515/jpm.2020.0132>

306 **Data Availability Statement**



307 The datasets analyzed for this study can be found in the Open Science Framework

308 Padilla-Raygoza N. COVID-19 in Mexican pregnant [Internet]. OSF; 2021. Available

309 from: <https://osf.io/b8hyw/>